论文部分内容阅读
目的:探讨当归补血汤对糖尿病大鼠足部病变的保护作用及其机制。方法:SD雄性大鼠腹腔注射链脲佐菌素(STZ)并结合室温控制以建立糖尿病足模型,给予当归补血汤或西洛他唑治疗。实验第3周末时,观察各组肢端坏疽并测定血糖情况。腹主动脉取血,测定血甘油三酯(TG)、胆固醇(TC)、高密度脂蛋白(HDL-C)、C反应蛋白(CRP)、C肽(CP)、糖化血红蛋白(GHb)。应用反转录多聚酶链反应技术(RT-PCR),观察各组大鼠小腿腓肠肌iNOSmRNA的表达情况。结果:STZ诱导的糖尿病大鼠存在明显的血糖、血脂及CRP、CP、GHb异常(P<0.01或<0.05),且出现不同程度的肢端坏疽。当归补血汤可以降低上述指标,减轻肢端坏疽(P<0.01或<0.05),而西洛他唑只改善了CRP和CP(P<0.01)。经给药处理3周后,当归补血汤组及西洛他唑组大鼠足部iNOSmRNA均有不同程度的下调(P<0.01)。结论:当归补血汤可改善血糖、血脂代谢紊乱,降低异常升高的GHb、CP、CRP水平,减轻肢端坏疽的症状,并能纠正升高的iNOSmRNA的表达,推测其能延缓高糖状态下的足部病变,对糖尿病足有一定的保护作用。
Objective: To investigate the protective effect of Dangguibuxuetang on foot lesion in diabetic rats and its mechanism. Methods: Male Sprague-Dawley rats were intraperitoneally injected with streptozotocin (STZ) and combined with room temperature control to establish a model of diabetic foot. The rats were treated with Dangguibuxuetang or cilostazol. At the end of the third week of experiment, the gangrenous gangrene in each group was observed and the blood glucose level was measured. Abdominal aorta blood was collected for determination of triglyceride (TG), cholesterol (TC), high density lipoprotein (HDL-C), C-reactive protein (CRP), C peptide (CP) and glycated hemoglobin (GHb). Reverse transcription polymerase chain reaction (RT-PCR) was used to observe the expression of iNOS mRNA in the calf muscle of each group. Results: There were significant abnormalities of blood glucose, blood lipid, CRP, CP, GHb in STZ-induced diabetic rats (P <0.01 or <0.05), and various degrees of gangrenous gangrene. Dangguibuxuetang can reduce the above indicators, reduce gangrenous gangrene (P <0.01 or <0.05), while cilostazol only improved CRP and CP (P <0.01). After 3 weeks of treatment, the iNOS mRNA in the foot of Dangguibuxue decoction group and cilostazol group were all decreased to some extent (P <0.01). Conclusion: Dangguibuxuetang can improve blood glucose and lipid metabolism disorder, reduce the abnormally elevated GHb, CP, CRP levels, reduce the symptoms of gangrenous gangrene and correct the increased expression of iNOSmRNA, suggesting that it can delay high glucose Foot lesions, have some protective effect on diabetic foot.